No connection

Search Results

ABBV vs HLN

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
HLN
Haleon plc
NEUTRAL
Price
$9.49
Market Cap
$42.18B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ABBV
163.63
HLN
18.98
Forward P/E
ABBV
15.42
HLN
15.63
P/B Ratio
ABBV
-146.66
HLN
1.9
P/S Ratio
ABBV
6.5
HLN
3.82
EV/EBITDA
ABBV
15.27
HLN
33.5

Profitability

Gross Margin
ABBV
71.46%
HLN
64.77%
Operating Margin
ABBV
35.5%
HLN
23.17%
Profit Margin
ABBV
4.0%
HLN
15.11%
ROE
ABBV
137.96%
HLN
10.27%
ROA
ABBV
9.59%
HLN
4.67%

Growth

Revenue Growth
ABBV
9.1%
HLN
0.6%
Earnings Growth
ABBV
-88.7%
HLN
92.0%

Financial Health

Debt/Equity
ABBV
--
HLN
0.52
Current Ratio
ABBV
0.72
HLN
0.92
Quick Ratio
ABBV
0.47
HLN
0.68

Dividends

Dividend Yield
ABBV
3.05%
HLN
2.01%
Payout Ratio
ABBV
490.15%
HLN
37.08%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
HLN NEUTRAL

Haleon plc presents a stable fundamental profile with a Piotroski F-Score of 6/9 and a current price of $9.49 that sits comfortably between its Graham Number ($7.49) and Intrinsic Value ($14.75). While the company exhibits strong profitability margins and a healthy debt-to-equity ratio of 0.52, it is hampered by stagnant revenue growth (0.60%) and a completely bearish technical trend (0/100). The massive spike in earnings growth (92%) appears decoupled from top-line performance, suggesting efficiency gains rather than market expansion. Overall, the stock is a value-play with limited immediate momentum.

Strengths
Strong gross margins at 64.77% and operating margins at 23.17%
Conservative leverage with a Debt/Equity ratio of 0.52
Stable financial health indicated by a Piotroski F-Score of 6/9
Risks
Near-zero revenue growth (0.60% YoY) indicating market saturation or lack of pricing power
Severe bearish technical momentum (Technical Trend: 0/100)
Liquidity concerns with a Quick Ratio of 0.68 and Current Ratio of 0.92

Compare Another Pair

ABBV vs HLN: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Haleon plc (HLN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile